RNTX grants director 17,500 options at $1.55 – Form 4 filing

Rein Therapeutics (RNTX) filed a Form 4 disclosing a routine equity grant to independent director Alan A. Musso.

Rhea-AI Filing Summary

Rein Therapeutics (RNTX) filed a Form 4 disclosing a routine equity grant to independent director Alan A. Musso. On 07/23/2025 Musso received 17,500 non-qualified stock options exercisable at $1.55 per share, equal to the grant-date market price. The award vests 100 % on the earlier of 07/23/2026 or the company’s 2026 annual meeting, conditional on continued board service. Following the transaction Musso beneficially owns 17,500 derivative securities and no additional common shares were reported. Ownership is held directly; no indirect holdings were disclosed.

No sale of shares, cashless exercise, or change in overall insider ownership occurred, so immediate dilution is de-minimis. The filing is primarily administrative, aligning director incentives with shareholders.

Insights

Securities Analyst

TL;DR: Routine director option grant; neutral impact on valuation, minor alignment benefit.

This Form 4 reports a standard equity incentive: 17,500 options at $1.55 (term ends 07/22/2035). The quantity is modest and cash-less until exercised, so dilution is negligible. Vesting over one year ties the director’s upside to share performance, a typical governance practice. No buying or selling activity was disclosed; therefore, the filing offers limited informational value for near-term trading decisions. I classify the disclosure as non-impactful to earnings, cash flow, or capital structure.

Insider Trade Summary

Grant/Award: 17,500 shares

Grant/Award 1 txn

Insider Musso Alan A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	17,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 17,500 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/23/2025 - 07:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Musso Alan A

(Last) (First) (Middle)

C/O REIN THERAPEUTICS, INC

12407 N. MOPAC EXPY. SUITE 250 #390

(Street)

AUSTIN TX 78758

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rein Therapeutics, Inc. [ RNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.55	07/23/2025		A		17,500		(1)	07/22/2035	Common Stock	17,500	$0.00	17,500	D

Explanation of Responses:

1. This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.

	/s/ Brian Windsor, attorney-in-fact for Alan A. Musso	07/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.